According to FutureWise analysis, the market for Adult Malignant Glioma Therapeutics is expected to grow at a CAGR of 9.50% over the forecast period of 2023-2031.
Malignant gliomas are brain tumors that originate from glial cells. They account for 28% of all primary brain tumors, yet they affect 80% of all malignant primary brain tumors in adults. The most common types of malignant gliomas include glioblastoma multiforme (GBM), anaplastic astrocytoma, and oligodendroglioma. Glioblastoma (GBM), a grade IV astrocytoma, is an aggressive and rapidly growing brain tumor. It invades the neighboring brain tissue but does not spread to distant organs. GBMs can either develop spontaneously in the brain or progress from lower-grade astrocytomas. In adults, GBM mostly occurs in the cerebrum, particularly in the frontal and temporal lobes.
The primary treatment for high-grade glioma patients includes surgical tumor removal, radiation, and chemotherapy. Surgical resection is often the initial step in treating malignant gliomas. The aim is to remove the tumor as much as possible without causing damage to brain regions. Radiation therapy, often using external beam radiation, is generally administered after surgery to target any remaining cancer cells. Techniques like intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery (SRS) can help deliver accurate radiation doses while minimizing damage to healthy brain tissue. Temozolomide (Temodar) is the most commonly used chemotherapy drug for malignant gliomas. It is an oral chemotherapy agent that is used in combination with radiation therapy. Other chemotherapy drugs, such as carmustine and lomustine, may also be considered.
FutureWise Market Research has published a report that provides an insightful adult malignant glioma therapeutics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts, adult malignant glioma therapeutics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.